Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma

Q4 Medicine

IJU Case Reports Pub Date : 2025-04-08 DOI:10.1002/iju5.70019

Keita Minami, Rei Narimatsu, Hajime Sasaki, Tatsu Tanabe, Hiroshi Tanaka

{"title":"Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma","authors":"Keita Minami, Rei Narimatsu, Hajime Sasaki, Tatsu Tanabe, Hiroshi Tanaka","doi":"10.1002/iju5.70019","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>We report a case in which enfortumab vedotin (EV) therapy was administered as a third-line treatment for locally advanced bladder cancer (<span>bc</span>), enabling successful radical resection.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>This report describes the case of a 69-year-old male patient with locally advanced <span>bc</span> and pelvic lymph node (LN) metastases. After the failure of first-line chemotherapy and second-line immunotherapy, the patient received EV as third-line treatment. EV therapy resulted in significant tumor reduction, enabling successful radical cystectomy and lymph node dissection (LND). The patient remained recurrence-free for 22 months post-surgery.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>EV therapy suggests that it is a promising avenue for further exploration, potentially redefining the therapeutic landscape of historically challenging cases.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 3","pages":"257-260"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70019","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

We report a case in which enfortumab vedotin (EV) therapy was administered as a third-line treatment for locally advanced bladder cancer (bc), enabling successful radical resection.

Case Presentation

This report describes the case of a 69-year-old male patient with locally advanced bc and pelvic lymph node (LN) metastases. After the failure of first-line chemotherapy and second-line immunotherapy, the patient received EV as third-line treatment. EV therapy resulted in significant tumor reduction, enabling successful radical cystectomy and lymph node dissection (LND). The patient remained recurrence-free for 22 months post-surgery.

Conclusion

EV therapy suggests that it is a promising avenue for further exploration, potentially redefining the therapeutic landscape of historically challenging cases.

Abstract Image

查看原文本刊更多论文

在晚期尿路上皮癌中应用维多汀治疗肿瘤显著缩小后的挽救性手术

我们报告了一个病例，强制维多汀（EV）治疗作为局部晚期膀胱癌（bc）的三线治疗，使根治性切除成功。本报告描述了一例69岁男性患者，局部晚期bc和盆腔淋巴结（LN）转移。在一线化疗和二线免疫治疗失败后，患者接受EV作为三线治疗。EV治疗导致肿瘤显著缩小，使根治性膀胱切除术和淋巴结清扫（LND）成功。患者术后22个月无复发。结论EV治疗是一种有前景的进一步探索途径，有可能重新定义历史上具有挑战性的病例的治疗前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊